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Abstract 
The centrally induced gastroprotective effect of neuropeptides has been intensively studied. 
Besides many similarities, however, differences can also be observed in their gastroprotective 
actions. The gastroprotective dose-response curve proved to be either sigmoid, or bell-shaped. 
Additional gastrointestinal effects of neuropeptides can contribute to their mucosal protective 
effect. Part of the neuropeptides induce gastroprotection by peripheral administration as well. 
Besides vagal nerve the sympathetic nervous system may also be involved in conveying the 
central effect to the periphery. Better understanding of the complex mechanism of the 
maintenance of gastric mucosal integrity may result in the development of new strategy to 
enhance gastric mucosal resistance against injury. 
1. Introduction. 
 The peripheral mechanisms responsible for gastric mucosal integrity have been revealed 
in many aspects. Several compounds, mediators have been demonstrated to play a role in the 
maintenance of mucosal integrity, like bicarbonate, mucus, phospholipids, trefoil peptides, 
prostaglandins (PGs), sensory neuropeptides, nitric oxide (NO), hydrogen sulfide, heat shock 
proteins, hypoxia-inducible factor-1 or various growths factors (for reviews see e.g. [1-
3,4**]). However, the role of the central nervous system (CNS) has also been raised in the 
regulation of gastric mucosal damage/protection. The dorsal vagal complex (DVC, including 
the dorsal motor nucleus of vagus (DMN), nucleus of the solitari tract (NTS) and area 
postrema) and the hypothamus have prominent role in the regulation of gastrointestinal 
functions and well defined interconnections between the neuroendocrine hypothalamus and 
the central autonomic system have been described [5]. 
 Lesion or electrical stimulation of different brain areas resulted in either development of 
gastric mucosal injury or stimulation of protective processes [6**]. However, most of the 
evidence on the involvement of CNS in regulation of gastric mucosal integrity came from 
pharmacological interventions. In the first experimental series mainly acid-dependent ulcer 
models were used, like stress-induced mucosal injury, which was inhibited by bombesin, 
neurotensin, β-endorphin, substance P or somatostatin injected into the cisterna magna 
(intracisternally, i.c.), or corticotropin-releasing factor (CRF) given into the amygdala or into 
the lateral brain ventricle (intracerebroventricularly, i.c.v.). Other peptides, like amylin 
(i.c.v.), bombesin or different opioids (injected i.c.) have been demonstrated to be effective in 
another acid-dependent, indomethacin-ulcer model [6**,7-8]. 
 A new chapter was opened when thyrotropin-releasing hormon (TRH), that plays a key 
role in the regulation of the autonomic nervous system, injected i.c. or into the DMN in low 
(0-5-1.5 ng), non-secretory dose was shown to inhibit the gastric mucosal damage against 
ethanol injury, which is an acid-independent ulcer model and widely used for the analysis of 
gastroprotective action [6**,9]. This finding initiated an intensive research, and as a result 
several neuropeptides were shown to be gastroprotective given centrally. For example, from 
the calcitonin family α-CGRP (i.c.), adrenomedullin (i.c.) and amylin (i.c.v.) were highly 
effective against mucosal injury induced by ethanol, while calcitonin (i.c.) aggravated the 
ethanol-induced lesions (but reduced stress-, i.c. injected TRH analogue- or aspirin-induced 
mucosal damage) [6**]. From the neuropeptide Y (NPY) family peptide YY (PYY) injected 
i.c. at doses subthreshold to stimulate gastric acid secretion exerted also gastroprotective 
effect against ethanol [6**]. Furthermore, several opioid peptides (β-endorphin, [D-
Ala(2),Phe(4),Gly(5)-ol]-enkephalin (DAGO), [D-Ala(2),D-Leu(5)]-enkephalin (DADLE), 
[D-Pen(2),D-Pen(5)]-enkephalin (DPDPE), deltorphin II, endomorphins) (i.c.v., i.c.), as well 
as cholecystokinin (CCK, i.c.v.), nociceptin, nocistatin (i.c.v.), substance P (i.c.v.) and 
angiotensin II (i.c.v.) inhibited the formation of ethanol-induced mucosal lesions [6**,10-12, 
13*,14*,15]. 
 A special group of neuropeptides, that besides possessing a key role in regulation of 
food intake, are likely to play a role in gastric mucosal defense as well, for example the above 
mentioned PYY, CCK and amylin, as well as ghrelin (i.c.v., ischemia-reperfusion model), 
orexin-A (i.c., ethanol-model), leptin (i.c.v., ethanol and ischemia-reperfusion) and nesfatin-1 
(i.c.v., ethanol). Moreover, TLQP-21, a vascular endothelial growth factor (VEGF)-derived 
peptide, which also may play a role in energy homeostatis, was also reported to exert 
gastroprotective effect given centrally (i.c.v., against ethanol) [6**,13*,14*,16, 17*,18]. 
 How the centrally injected neuropeptides can induce gastric mucosal protection in the 
periphery, in gastric mucosa? Convincing evidence suggests the role of vagal nerve in 
conveying the central stimulus to the periphery. Several neuropeptides seem to induce vagal-
dependent central gastroprotection, such as TRH (i.c., DMN) [6**,9], adrenomedullin (i.c.) 
[19], PYY (i.c.) [20], amylin (i.c.v.) [21], leptin and CCK (i.c.v.) [12], ghrelin (i.c.v.) [22], 
opioids, e.g. β-endorphin, deltorphin II, endomorphins (i.c.v., i.c.) [14*,23], nociceptin and 
nocistatin (i.c.v.) [24,25], TLQP-21 (i.c.v.) [16], substance P (i.c.v.) [10], orexin-A (i.c.) [18], 
angiotensin II (i.c.v.) [15] or nesfatin-1 (i.c.v.) [17*]. The peripheral mechanism of vagally 
mediated gastroprotective effect has been well documented by biochemical and 
pharmacological studies, suggesting that the activation of vagal cholinergic pathways 
stimulates the release of gastric mucosal PG and NO, as well as the effector function of 
capsaicin-sensitive afferent fibers containing calcitonin gene-related peptide (CGRP) [6**]. 
 Though centrally injected neuropeptides induce gastroprotection mainly by common 
mechanisms, several differences have been demonstrated in their protective profile (Figure 1). 
The aim of this review is to compare the 
- gastroprotective dose range, 
- dose-response relationships, 
- additional gastrointestinal effects and interactions with other neuropeptides, 
- central / peripheral effectiveness, 
- pathways that convey the central action to the periphery of neuropeptides. 
 
2. Differences in the gastroprotective effect of neuropeptides 
2.1. The gastroprotective dose range 
 Neuropeptides injected i.c.v. or i.c. can be devided into different groups according to 
their gastroprotective dose range (Table 1). The differences in the effective dose range can be 
due to several reasons, such as different intrinsic activities, partial/full agonistic property, 
permeation of the peptides to their receptors, density of their receptors in the site of action 
(e.g. dorsal vagal complex) or interactions with other neuropeptides / mediators. 
 
2.2. Dose-reponse relationships 
 The dose-reponse curves of neuropeptides proved to be partly sigmoid, partly bell-
shaped (Figure 2). It has been recognized already 40 years ago, that increasing the dose of a 
peptide the effect, after reaching a platue, can decrease, disappear or even reverse. Common 
characteristic of the bell-shaped (also called inverted U-shaped or hormetic) dose-response 
relationships is that the reduced or reversed effect may be expected typically in 10- and 100-
fold of the stimulatory (inhibitory) dose-range (though the range can also be much wider) (for 
reviews see [26,27]). 
 Bell-shaped dose-reponse relationship was observed for example with RX 77368 (a 
stable TRH analog) [28], adrenomedullin [29], nociceptin and nocistatin [25], substance P 
[10] and angiotensin II [15]. In most cases the gastroprotective ranges varied between 10- and 
100-fold, which is in agreement with the biphasic responses observed in other fields. 
 On the other hand, with other neuropeptides, such as ghrelin, opioids, amylin or 
nesfatin-1 the mucosal protective effect did not decline at higher doses, despite of the wide 
tested dose ranges [17*,21,23,30]. 
 Interestingly, however, ghrelin or amylin has biphasic effects on other gastrointestinal 
functions (gastric emptying, gastric acid secretion) [31,32]. The phenomenon of bell-shaped 
or biphasic dose-response relationship of neuropeptides should be also considered in study 
designs both under experimental conditions and human trials. 
 Although the bell-shaped effect is rather commonly observed, the analysis of the 
underlying mechanism in most cases is lacking. In some cases it can be resulted from a mixed 
agonist/antagonist action mediated by different receptor populations. Khan et al. [33] for 
example reported that the biphasic effect of substance P on striatal dopamine outflow is 
determined by the balance between muscarinic M1 (stimulatory) and M2 (inhibitory) 
receptors. 
 Another possibility is that additional gastrointestinal effects, e.g. increased gastric acid 
secretion or altered gastric motility may counteract the mucosal protective action at higher 
doses. Moreover, interactions between neuropeptides may also modify the gastroprotective 
effect. 
 
2.3. Additional gastrointestinal effects and interactions of neuropeptides 
 TRH in higher dose range than the gastroprotective one stimulates gastric acid secretion, 
gastric motor activity and aggravates experimentally induced gastric mucosal lesions [35]. In 
contrast, nociceptin (possessing a bell-shaped dose-response curve) exerts inhibitory effect on 
gastric acid secretion even in 10-50 times higher dose range than the gastroprotective one 
(0.2-1 nmol vs. 10 nmol) and reduces gastrointestinal motor activity as well [36]. In contrast, 
ghrelin inhibits ischemia/reperfusion-induced mucosal lesions given i.c.v., but increases 
gastric acid secretion in the same dose range [22]. Moreover, ghrelin injected into the IVth 
ventricle or into the DVC elicited contractions of the gastric corpus via excitation of a vagal 
cholinergic efferent pathway [37], however, ghrelin-induced gastroprotective effect was not 
reduced in higher dose range. The above data suggest the lack of a definitive correlation 
between the declined gastroprotective effect and the increased gastric acid secretion or gastric 
motor activity. 
 In addition, numerous interactions of neuropeptides with each other or with other 
mediators have been described. The interactions (due for example to stimulation of the 
release, co-expression and co-release of neuropeptides, co-expression of the receptors) may 
result in augmentation or inhibition of the gastroprotective effect. Some examples: 
endogenous opioids are involved in the gastroprotective effect of nociceptin, nocistatin, 
endocannabinoids and substance P [25,38], or the endocannabinoid, 2-arachidonoylglycerol is 
likely to play a role in the centrally induced gastroprotective effect of angiotensin II [15]. 
Moreover, interactions between leptin and CCK [12] as well as RX 77368 and the PYY 
agonist [Pro34]PYY have been described in the ethanol ulcer model [39]. In addition, 
interaction between TRH and leptin in the DVC was described where TRH1 and leptin 
receptors are co-localized [40]. Furthermore, CCK were shown to activate orexin and 
neurotensin neurons [41], endomorphin-2 is co-localized with SP and CGRP in the NTS [42] 
and the peripherally (i.v.) given neurotensin may induce gastroprotection by activating the 
central endocannabinoid system [43]. Recently cannabinoids were demonstrated to affect the 
expression of hypothalamic neuropeptides, notably the NPY and β-endorphin systems, which 
may be involved in the orexigenic and gastroprotective action of cannabinoids [44]. 
 These few, selected data suggest a complex interaction of neuropeptides with each other 
and with other mediators of the CNS, which may modify their gastroprotective action. Further 
studies are needed to clarify the role of interaction of neuropeptides in gastric mucosal 
homeostasis. 
 
2.4. Gastroprotection initiated centrally or peripherally 
 Some of the neuropeptides are protective only after central administration, and given 
peripherally either lack of effect, or even aggravation of mucosal damage can be observed. 
Such a phenomenon has been reported e.g. for amylin [21], adrenomedullin [19], TLQP-21 
[16], or recently with angiotensin II [15,45] and substance P [10]. It might be speculated that 
some neuropeptides, especially in higher doses, are able to cross the brain-blood barrier by 
non-saturable or saturable transport mechanisms using transporters (recently reviewed by 
Banks [46**]) and enter the systemic circulation, where they may counteract the centrally-
induced gastroprotective action via peripheral mechanisms. For example, the dose-reponse 
curve of angiotensin II and substance P injected i.c.v. proved to be bell-shaped (see above) 
and both peptides aggravated the mucosal lesions after peripheral administration, partly due to 
increased formation of reactive oxygen species [47,48]. 
 On the other hand, numerous peptides exert mucosal protective action given both 
centrally and peripherally, like neurotensin, nesfatin-1, nociceptin, ghrelin or opioid peptides, 
such as DADLE, DPDPE and deltorphin II [17*,22-25,43,49], however, the central and 
peripheral effective dose ranges are rather different. For example, the ratios of the peripheral 
and central gastroprotective doses (calculated on the basis of literature data comparing either 
the ED50 values, or the doses resulting in approximately the same gastroprotective action) are 
approximately 5000 for deltorphin (ethanol-injury) [23,49], 200-500 for DPDPE and 
neurotensin (ethanol-injury) [23,43,49], 20-80 for leptin and DADLE (ethanol-injury) 
[12,23,49,50] and below 10 for nesfatin-1, ghrelin, CCK-8 and nociceptin (water immersion 
restrain stress-, and ethanol-induced injury) [12,17*,24,25,50]. Also a peripherally injected 
neuropeptide may induce gastroprotective action by central mechanism, for example, as 
mentioned in the previous section, central cannabinoid CB1 receptors are likely to mediate (at 
least partly) the gastroprotective effect of peripherally given neurotensin [43]. 
 
2.5. Factors conveying the centrally inititated effect to the periphery 
 As mentioned above, vagally mediated gastroprotective effect has been demonstrated 
for the majority of neuropeptides. However, several data suggest that besides vagal nerve 
other mechanisms may also play a role in conveying the centrally initiated effect to the 
periphery. For example both adrenergic and cholinergic systems are likely to be involved in 
the gastroprotective effect of centrally injected ghrelin, since only parallel inhibition of both 
systems were able to abolish it [51]. Furthermore, the gastroprotective effect of angiotensin II 
injected into the paraventricular nucleus of the hypothalamus was not affected by 
subdiaphragmatic vagotomy or atropine, but was abolished by propranolol or disconnection of 
the nerves innervating the adrenal glands indicating the importance of the sympathetic-adrenal 
gland/beta-adrenoceptor pathway [52]. The gastroprotective effect of nociceptin was blocked 
by atropine, subdiaphragmatic vagotomy and bretylium, suggesting that both vagal 
cholinergic and sympathetic pathways mediate the central activity of this peptide [53]. 
Moreover, the protective action of neurotensin injected i.c.v. or into the n. accumbens was 
ameliorated by pretreatment with 6-hydroxydopamine into the mesolimbic nuclei [54]. Our 
recent findings also confirmed the role of sympathetic nervous system in centrally induced 
gastroprotection. The gastroprotective effect of opioid peptides was reduced both following 
bilateral cervical vagotomy and after chemical sympathectomy by 6-hydroxydopamine 
(i.c.v.). The later action was correlated with the reduction of the noradrenaline content in the 
NTS [13*]. 
 Furher studies are needed to reveal how sympathetic nervous system may mediate the 
centrally initiated mucosal protective effect. It should be assumed that DMN besides 
supplying parasympathetic pre-ganglionic fibers to the viscera contains neurons with diverse 
neurochemical phenotypes. For example, neurons with tyrosine hydroxylase 
immunoreactivity (TH-IR) have been identified in the DMN, as well as dopamine β-
hydroxylase neurons were shown in the DVC (similar in number and distribution as TH-IR). 
It may be concluded that the TH-IR positive neurons in the DMN are capable of synthesizing 
norepinephrine. Moreover, these TH-IR-positive caudal DMV neurons have been 
demonstrated to display choline acetyltransferase activity as well [55] suggesting that 
activation of DVC may result in activation of both the cholinergic and adrenergic system to 
the peripheral targets. 
 
3. Conclusion 
 Increasing number of evidence suggests the crucial role of neuropeptides in gastric 
mucosal integrity. However, several questions remained to be answered to elucidate their 
precise role in this process. For example, further studies are needed to clarify: whether 
changes of endogenous level of neuropeptides may result in gastroprotective (or damaging) 
effect; the precise anatomical background (brain areas, projections) involved in regulation of 
mucosal integrity; relevance of  neuropeptide-interactions in gastroprotection; how the 
effective gastroprotective dose range relates to other actions of the neuropeptides; and the 
importance of the blood-brain and brain-blood transport of neuropeptides. It may be 
speculated that since some peptides using transporters can enter the brain following peripheral 
administration (46**), they may induce gastroprotective effect by central mechanism. Vice 
versa, the brain-to-blood transport might result also peripheral effect following central 
adminsitration of the peptides. Peripheral administration of peptides or peptide analogues 
which can cross the bood-brain barrier, or agents that may modify the endogenous level of 
gastroprotective neuropeptides might represent new therapeutic possibilities against gastric 
mucosal injury. Moreover, better understanding of the complex (and virtually redundant) 
mechanism of the maintenance of gastric mucosal integrity may serve as a basis for the 
development of new strategies to enhance gastric mucosal resistance against injury. 
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Legends 
 
Figure 1. Similarities and differences between the centrally induced gastroprotective effect of 
neuropeptides. 
 
Figure 2. Dose-response relationships of various gastroprotective neuropeptides. Based on the 
data in references [10,15,16,17*,21-23,25,28,34]. 
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Central dose (pmol / rat) 
  RX 77368 (DMN) 
  Nociceptin (i.c.v.) 
  Nocistatin (i.c.v.) 
  Substance P (i.c.v.) 
  Angiotensin II (i.c.v.) 
  Ghrelin (i.c.v.) 
  β-endorphin (i.c.v.) 
  Nesfatin-1 (i.c.v.) 
  TLQP-21 (i.c.v.) 
  Amylin (i.c.v.) 
Figure 2
Gastroprotective 
dose range 
Route of administration 
i.c.v. i.c. 
< 1 pmol EMs 
 β-endorphin 
1 - 10 pmol 
β-endorphin 
SP 
 TRH, DAGO 
10 - 100 pmol 
Nesfatin-1 Leptin 
Ang II PYY 
Adrenomedullin 
100 - 1000 pmol TLQP-1 
N/OFQ, NST Deltorphin II 
> 1000 pmol 
Ghrelin Deltorphin II Orexin-A 
 
Table 1. Groups of neuropeptides according to their gastroprotective dose range. 
Abbreviations: EMs – endomorphins; SP – substance P; Ang II – angiotensin II; N/OFQ – 
nociception; NST – nocistatin. Based on the data in references [10,13*,15,17*,18,23]. 
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